MIMS summary of new treatment: Olumiant (baricitinib) for treatment of adults with moderate to severe atopic dermatitis

A brief summary is provided of data from three randomised, double-blind, placebo-controlled 16-week phase III studies (BREEZE-AD1, AD2, and AD7), which examined its efficacy and safety as either monotherapy or in combination with topical corticosteroids.

Source:

Monthly Index of Medical Specialities